2015 American Transplant Congress
Calcineurin Inhibitors (CNI) Minimization Associated With Mammalian Target of Rapamycin Inhibitors (i-mTOR) to Improve Renal Function in Renal Grafts from Uncontrolled Donation After Cardiac Death Donors (UDCDD)
INTRODUCTION: Ischemia injury in kidneys grafts from UDCDD could produce a poor renal function. Minimized blood levels of CNI associated with i-mTOR therapy could avoid…2015 American Transplant Congress
Incidence of Hepatitis B Virus Reactivation in Kidney Transplant Patients Who Received Rituximab Administration
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
OBJECTIVE:The efficacy of antiviral prophylaxis for rituximab (RIT)-associated hepatitis B virus (HBV) reactivation in patients with lymphoma has been recently reported. However, the immunological effect…2015 American Transplant Congress
Efficacy and Safety of Three Different Treatment Regimen in De Novo Renal Transplant Patients: Month 48 Follow-Up Results of the HERAKLES Trial
Aim: To compare safety and efficacy of 3 different immunosuppressive (IS) regimen 4years after renal transplantation (Tx).Methods: 802 patients (pts) were included in this 1year,…2015 American Transplant Congress
Clinical and Pathologic Predictors of Response to Belatacept Conversion
Columbia Universtiy, New York.
INTRO: Calcineurin inhibitors have improved kidney transplant and recipient survival, their use has significant nephrotoxicity. Belatacept is a recently approved immunosuppressant that is not nephrotoxic…2015 American Transplant Congress
Belatacept-Treated Patients Had Better Graft Survival at 7-Years Post-Transplant Compared With Cyclosporine-Treated Patients: Final Results from BENEFIT
Background: At 3yrs, improvement in renal function was seen in kidney transplant recipients treated with belatacept (bela) vs cyclosporine (CsA) in BENEFIT. Here we report…2015 American Transplant Congress
Clinical Utility of Allospecific CD154+T-Cells in Children With Liver Or Intestine Transplantation (LTx, ITx)
Background: Allospecific CD154+T-cytotoxic memory (CD154+TcM) have completed investigational evaluation as predictors of acute cellular rejection in children with LTx or ITx.Purpose: To evaluate CD154+TcM** as…2015 American Transplant Congress
Dual PI3K-mTOR Inhibition on Human T Cell Activation, Proliferation, and Differentiation: The First Step in the Development of New Immunosuppressants
Background: Regulatory T lymphocytes (Tregs) contribute to transplant tolerance. We have demonstrated that the inhibition of PI3K-mTOR pathway has a major role in the differentiation…2015 American Transplant Congress
Induction of iNOS Expressed Macrophages from Mouse iPS cells That Contribute to Prolong Same iPS Cells-Derived Graft Survival in Allogeneic Recipients
BACKGROUND: Induced pluripotent stem cells (iPSCs)-technology provides new opportunities in regenerative medicine to generate grafts from donors for transplantation. However, particularly when allogeneic iPSCs are…2015 American Transplant Congress
Variants Associated With Tacrolimus Troughs in European American Kidney Transplant Recipients: A Genome Wide Association Study
Tacrolimus (tac) is dependent on CYP3A4/5 for metabolism. Variability in the metabolism is influenced by CYP3A5*3 alleles. This variant and clinical factors explain around 50%…2015 American Transplant Congress
Does Infection Impact On Tacrolimus Blood Levels in Kidney Transplant Recipients?
Background Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy in kidney transplant recipients. It is metabolized by members of the cytochrome p450 (CYP) 3A subfamily…
American Transplant Congress abstracts